CardioSCORE’s blood test earns CE Mark

CardioSCORE, a diagnostic blood test designed to improve risk prediction of major cardiovascular events beyond traditional risk factor assessments, has received CE Mark approval in Europe.

The CardioSCORE test is performed on a standard blood sample and uses algorithmic analysis to combine the results of seven protein assays, according to Waltham, Mass.-based BG Medicine, a company that develops and commercializes cardiovascular tests. CardioSCORE provides an independent scoring system that yields a quantitative result ranging from 0 to 10, with higher values indicating elevated risk for a major cardiovascular event in the subsequent three years and with each one-point increment representing a 30 percent increase in relative risk.

In the 6,600 patient BioImage study cohort, the primary clinical validation study for the CardioSCORE test, among those who experienced a near-term major cardiovascular event during follow-up, 26 percent were identified as being at high risk at baseline by traditional risk factors, while 54 percent were identified as being at high risk with the addition of a CardioSCORE result.

The CardioSCORE test is not yet available commercially in the U.S. BG Medicine said it is discussing 510(k) clearance with the FDA.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup